These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 21674876)

  • 1. Recurrent episodes of recall dermatitis of irradiated breast after LHRH agonist administration.
    Kostadima L; Pentheroudakis G; Pavlidis N
    J BUON; 2011; 16(1):183-4. PubMed ID: 21674876
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug eruption induced by gonadotropin-releasing hormone analogs accompanying radiation-recall phenomenon.
    Oshima M; Murao K; Ishigami T; Kubo Y
    J Dermatol; 2012 Dec; 39(12):1080-1. PubMed ID: 22568476
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adverse reaction of LH-RH agonist and its countermeasure].
    Oishi K
    Nihon Rinsho; 2000 Jul; 58 Suppl():202-5. PubMed ID: 11022714
    [No Abstract]   [Full Text] [Related]  

  • 6. [The use of Ovestin to overcome the side effects of treatment with GnRH agonists (Zoladex)].
    Ivanov S; Ivanov S
    Akush Ginekol (Sofiia); 1998; 37(4):25-6. PubMed ID: 10360048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of LH-RH agonist for bone metastases of breast cancer--report of a case].
    Kudoh S; Kawamura H; Suzuki Y; Matsuzaki M; Nishina M; Tsukamoto M
    Gan To Kagaku Ryoho; 1996 May; 23(6):787-90. PubMed ID: 8645031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fertility preservation in (breast) cancer patients: is it safe?
    Wildiers H; Neven P; Amant F; D'hooghe T; Paridaens R
    J Clin Oncol; 2006 Nov; 24(33):5335-6; author reply 5337-8. PubMed ID: 17114672
    [No Abstract]   [Full Text] [Related]  

  • 9. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
    Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
    Bong GW; Clarke HS; Hancock WC; Keane TE
    Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
    Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulomas induced by subcutaneous injection of a luteinizing hormone-releasing hormone analog: a case report and review of the literature.
    Watanabe T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2010 Oct; 37(10):1116-8. PubMed ID: 19863702
    [No Abstract]   [Full Text] [Related]  

  • 14. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drawbacks of ovarian ablation with goserelin in women with breast cancer].
    Franco S; Lupa P; Guerra C; Pereira L; Oliveira CF
    Acta Med Port; 2005; 18(2):123-7. PubMed ID: 16202345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of menstruation recovery after LH-RH agonist therapy for premenopausal patients with breast cancer.
    Matsumoto M; Miyauchi M; Yamamoto N; Shishikura T; Imanaka N
    Breast Cancer; 2000; 7(3):237-40. PubMed ID: 11029804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
    Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
    Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.